All the other noise does not matter, pipeline, CEO, etc. we have to fix the revenue stream from Belviq, we have nothing else to sell except the whole company, and at this point that is what is best for the shareholder IMO.
His last article summary of patients....12 to 13 weeks they hit the wall for weight loss as they have also not made any significant lifestyle changes to sustain continued weight loss. Boom, they drop Bel because of cost, and their results. Eisai must produce very costly ads to sustain any new script growth to cover those that drop off.........that course of action is cost prohibitive for Eisia to continue operating at a big loss. If Bel X makes it to market, the same thing will occur, going through the same patient turn over cycle. Something I figured out long ago.......American's (on the whole) are not making the lifestyle changes needed to get sustained weight loss, and the drug is too expensive to remain taking it. A marketing dilemma, and a huge problem for this drug (Eisai) to overcome to make it a success, and profitable for both parties. I question if they can achieve that goal.
Two things need to happen.........ASAP new markets to open for revenue income, and the other two weight drugs fade away due to the same reason, leaving Bel with a bigger market share.
** Overall, I have no idea where the breakeven revenue point for Eisia is in dollars needed, but is clear they ain't there yet, and don't expect to be!
A key issue to consider? If there is a past pending offer to re-consider by the BOD's they should take it forward to the shareholders. This would clean up the mess, and they would become hero's and exit with full pockets after the sale. Everyone is happy....give me $8 pps and some new stock.
Think about it.......At this point, and for the near future, the New Arena is still the Old Arena even with Jack"O" gone. It takes a nautical mile to make a 180 degree turn on a big ship. Moral of the story, it takes longer than you would all like to turn things around. Bring in Trump.
That should explain this whole mess......falling scripts, doctors not aware, and many doctors don't care. Thanks Eisai for a #$%$ roll out. Jack"O" is gone now, do we get a "Mulligan"? Don't count on it from Wall Street, they don't give Mulligans. Let's face it, the weight loss drug market has failed, no money to be made on this stock, scripts would have to double from where we are at for any PPS evaluation over $7
Wall Street may support a new CEO, and the price already is baked in for that event. Nothing is going to get this back to $3.00 until sales turn around, or a buy out offer is on the table. JMO.....the company is in real trouble, CFO gone, CEO, gone, sales declining, ads cut back, no new markets, burning cash, no hope for pipeline trials to continue/complete soon, and a dilution around the bend. Who wants to hold for another two years or more....raise your hand?
Probably right in some aspects. When a CEO remains silent, discloses very little, provides vague outlook for the future, avoids conference questions, it means there is not much good to discuss, or disclose so they keep quite. Jack's been quite for over two years, the company has had very minimal PR. Old adage...."If you don't have anything good to say, then don't say anything."
He should give back about 50 million to the company, and take nothing more than his last pay check....Thief!
Any one else feel like a toast! I am a happy camper today after this news. Six years owning this stock, maybe a chance to recover, tomorrows open will tell us something. Nice volume today courtesy of some early leaks of the news.
The uncertainty was keep Lief as the CEO......his plan was uncertain, not communicated, no direction. Wall Street will see the change as positive, just like the board does. A step to turn things around. This is a good day!
I would take the $10 in a heart beat. With the alternative being staying on the same path JL has taken, and probably will continue for the near future.......$10 is an early Christmas Gift.
It's balance sheet adjustment for P&L......I can hardly call it cash revenue, and it won't make the payroll any easier, pay the bills, or make the stock PPS move .10 cents and not a worthy argument to save the financial condition this company faces.